MCID: ACT224
MIFTS: 10

Acute Promyelocytic Leukemia Pml/rara Type malady

Categories: Genetic diseases, Cancer diseases

Aliases & Classifications for Acute Promyelocytic Leukemia Pml/rara Type

Aliases & Descriptions for Acute Promyelocytic Leukemia Pml/rara Type:

Name: Acute Promyelocytic Leukemia Pml/rara Type 24
Leukemia, Acute Promyelocytic, Pml/rara Type 24

Classifications:



Summaries for Acute Promyelocytic Leukemia Pml/rara Type

MalaCards based summary : Acute Promyelocytic Leukemia Pml/rara Type, is also known as leukemia, acute promyelocytic, pml/rara type. An important gene associated with Acute Promyelocytic Leukemia Pml/rara Type is PML (Promyelocytic Leukemia). The drugs Idarubicin and Arsenic trioxide have been mentioned in the context of this disorder.

Related Diseases for Acute Promyelocytic Leukemia Pml/rara Type

Symptoms & Phenotypes for Acute Promyelocytic Leukemia Pml/rara Type

Drugs & Therapeutics for Acute Promyelocytic Leukemia Pml/rara Type

Drugs for Acute Promyelocytic Leukemia Pml/rara Type (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Idarubicin Approved Phase 4,Phase 3,Phase 1 58957-92-9 42890
2
Arsenic trioxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1327-53-3 518740
3
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
4
Tretinoin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2 302-79-4 5538
5 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
6 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
7 6-Mercaptopurine Phase 4,Phase 3,Phase 2
8 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
9
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
10
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
11
Mitoxantrone Approved, Investigational Phase 3,Phase 1 65271-80-9 4212
12
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 54575, 6560146 143
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
14
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 11103-57-4, 68-26-8 445354
15 Dermatologic Agents Phase 3,Phase 2,Phase 1
16 Keratolytic Agents Phase 3,Phase 2,Phase 1
17 Folic Acid Antagonists Phase 3,Phase 2
18 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
19 Trace Elements Phase 3,Phase 1
20 Vitamin B Complex Phase 3,Phase 2,Phase 1
21 Vitamins Phase 3,Phase 1
22 Anti-Infective Agents Phase 3,Phase 2,Phase 1
23 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
24 Antimetabolites Phase 3,Phase 2,Phase 1
25 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
26 Micronutrients Phase 3,Phase 1
27 Antirheumatic Agents Phase 3,Phase 2
28 Antiviral Agents Phase 3,Phase 2,Phase 1
29 Dexamethasone acetate Phase 3 1177-87-3
30 Analgesics Phase 3,Phase 1
31 glucocorticoids Phase 3
32
protease inhibitors Phase 3
33 Gastrointestinal Agents Phase 3
34 HIV Protease Inhibitors Phase 3
35 Hormone Antagonists Phase 3
36 Dexamethasone 21-phosphate Phase 3
37 Hormones Phase 3
38 Peripheral Nervous System Agents Phase 3,Phase 1
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
40 Protective Agents Phase 3
41 Antiemetics Phase 3
42 Anti-Inflammatory Agents Phase 3
43 Retinol palmitate Phase 3
44 BB 1101 Phase 3
45 Autonomic Agents Phase 3
46 Antineoplastic Agents, Hormonal Phase 3
47 Antioxidants Phase 3
48 Folate Nutraceutical Phase 3,Phase 2,Phase 1
49 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1
50 retinol Nutraceutical Phase 3

Interventional clinical trials:

(show all 23)
id Name Status NCT ID Phase
1 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Unknown status NCT00196768 Phase 4
2 Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4
3 Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Completed NCT00465933 Phase 4
4 Acute Promyelocytic Leukemia 2006 (APL) Unknown status NCT00378365 Phase 3
5 Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia Recruiting NCT02688140 Phase 3
6 Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia Recruiting NCT02339740 Phase 3
7 Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia Recruiting NCT01226303 Phase 3
8 Phase III Trial in Acute Promyelocytic Leukemia Patients Active, not recruiting NCT00482833 Phase 3
9 AIDA 2000 Guidelines Unknown status NCT01064570 Phase 2
10 Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Unknown status NCT00675870 Phase 2
11 Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia Completed NCT00008697 Phase 1, Phase 2
12 Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia Completed NCT00276601 Phase 2
13 Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Completed NCT00313586 Phase 2
14 Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Active, not recruiting NCT00105001 Phase 2
15 Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT01130506 Phase 1
16 Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia Completed NCT01132586 Phase 1
17 Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00217646 Phase 1
18 Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases Completed NCT00351975 Phase 1
19 Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia Active, not recruiting NCT01249430 Phase 1
20 Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers Active, not recruiting NCT01254578 Phase 1
21 Veliparib and Temozolomide in Treating Patients With Acute Leukemia Active, not recruiting NCT01139970 Phase 1
22 Biomarkers in Tissue Samples From Patients With Acute Promyelocytic Leukemia Completed NCT01232855
23 Laboratory-Treated Donor Cord Blood Cell Infusion Following Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting NCT01701323

Search NIH Clinical Center for Acute Promyelocytic Leukemia Pml/rara Type

Genetic Tests for Acute Promyelocytic Leukemia Pml/rara Type

Genetic tests related to Acute Promyelocytic Leukemia Pml/rara Type:

id Genetic test Affiliating Genes
1 Acute Promyelocytic Leukemia Pml/rara Type 24 PML

Anatomical Context for Acute Promyelocytic Leukemia Pml/rara Type

Publications for Acute Promyelocytic Leukemia Pml/rara Type

Variations for Acute Promyelocytic Leukemia Pml/rara Type

Expression for Acute Promyelocytic Leukemia Pml/rara Type

Search GEO for disease gene expression data for Acute Promyelocytic Leukemia Pml/rara Type.

Pathways for Acute Promyelocytic Leukemia Pml/rara Type

GO Terms for Acute Promyelocytic Leukemia Pml/rara Type

Sources for Acute Promyelocytic Leukemia Pml/rara Type

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....